Beth Hecht - 03 Jan 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Beth Hecht
Issuer symbol
XERS
Transactions as of
03 Jan 2025
Net transactions value
-$115,661
Form type
4
Filing time
07 Jan 2025, 16:40:54 UTC
Previous filing
31 Jan 2024
Next filing
03 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $115,661 -32,039 -2.3% $3.61 1,352,794 03 Jan 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025.
F2 Includes 4,031 shares acquired on December 31, 2024 under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended.

Remarks:

Chief Legal Officer and Corporate Secretary